ICER says AstraZeneca’s new blood pressure med isn’t cost-effective

negativeBaxfendyNegative

AI Analysis

Summary

ICER issued a report concluding that AstraZeneca's blood pressure medication Baxfendy does not provide sufficient clinical benefits to justify its $10,950 annual price tag, raising concerns about reimbursement and market access.

Outcome Details

ICER concluded the drug's benefits do not justify the $10,950 per year price tag

Importance:5/10

Sentiment:

-0.65

pricingcost-effectivenessICERhypertensionreimbursement

Related Companies

$AZN

Read the original article

Published by Endpoints News on August 14, 2026 3:15 PM

Read Original